ADM
Tronics Achieves
Development Milestone for Alvio Respiratory Therapy
Platform
Northvale, NJ --
October 16, 2018 -- InvestorsHub NewsWire -- ADM Tronics Unlimited,
Inc. (OTCQB -
ADMT) has achieved a
milestone in
the
development of
the Alvio Respiratory
Therapy platform ("Alvio").
ADMT has completed development
and engineering
to
bring Alvio
to
production-ready
status. All components
are
now in place for
the
initial
100-unit
production
run, being assembled
now. This
initial
run of
Alvio devices will be deployed for patient and clinic
testing. As announced last
November, ADM entered into an
agreement with QoL Devices, Inc., a
private company ("QoL")
for
development, regulatory
activities and manufacturing
of Alvio.
The Alvio
platform
is targeted for use in
non-regulated respiratory training applications as well as for
medical respiratory indications.
"We are so pleased we
are ready for
production of our
first Alvio units," stated Bez Arkush, founder and
President
of QoL. "This is a significant milestone for our
respiratory
technology that has the potential to help millions of people. We
are excited to have made this
progress with ADMT."
The
initial
Alvio
production
units are
slated for user and clinic
testing including testing at the Mayo Clinic under the direction of
Dr. Bruce Johnson. Dr. Johnson has dedicated his research to
improving
treatment
of patients with pulmonary conditions. Research
prototypes of the
Alvio platform were previously
successfully
evaluated in Dr. Johnson's lab.
ADMT has
developed and engineered
all the
supply chain components required to manufacture Alvio devices
in ADMT's
FDA-registered
medical device manufacturing facility. QoL and ADMT plan to
first introduce a non-regulated version
of Alvio for sale to consumers
for
breathing training, while preparing submission to FDA for clearance
of Alvio for medical applications in the US and for CE
marking for Europe.
A study was conducted
at Children's
Hospital at Montefiore Medical Center in New York
titled
"Engagement and interest of children and their parents in a gaming
device to assess lung function."
In the
study, asthmatic children
utilized the gaming
functionality of the Alvio platform to facilitate lung function
assessment of asthma monitoring to improve health outcomes. The
results showed a highly significant result with 92% of
children wanting to use the gaming function of the
device
and 95%
of parents interested in using the games to better understand their
child's lung function. The study
concluded, "This
study supports the accessibility and interest in using a gaming
device to assess lung function. Making lung
function testing accessible and fun could increase use of testing
to improve asthma management."
Over 80 million
people in the US and over 1 billion
people worldwide suffer
with
respiratory
challenges such as Asthma,
COPD
(chronic obstructive
pulmonary
disease) and
CHF
(congestive heart failure). These patients
require
special breathing monitoring, training,
and therapeutic devices in
the
hospital
and at home. Alvio's cloud-connected devices
can serve as an enabler
to lower costs and improve patient outcomes across the continuum of
care in the hospital and
at home.
"We believe our
devices are positioned to disrupt
the $5+ billion US
and the
$6+ billion
international respiratory
therapy markets.
Alvio is the world's only
fully integrated respiratory therapy
platform, mobile connected,
respiratory sensor and trainer that can
redefine respiratory
therapy and training markets," continued Mr. Arkush.
Andre' DiMino, ADMT
President stated
"We are excited to
have reached this milestone in the development of Alvio which has
the potential to help so many with debilitating respiratory
problems. It is especially gratifying to me to be bringing forward
a technology that can help children with asthma."
ADMT
is an
equity
holder in QoL.
Alvio
can
provide
an end-to-end solution for lung function testing, respiratory
training, and data tracking, utilizing an
interactive connection among patients, caregivers,
health care providers, and
payers. Alvio employs games and activities
to incentivize patients to complete
respiratory therapy,
overcoming non-compliance
issues that plague
conventional
respiratory devices. The
Alvio
platform can solve
a major
challenge in the healthcare market by
offering the next generation of a combination of data
and device connectivity - it's
Respiratory
Therapy
2.0.
About ADMT
ADMT is a
diversified, technology-based developer and manufacturer of
innovative technologies and products. Its core competency is its
ability to conceptualize a technology, bring it through
development, into manufacturing and commercialization, all
in-house. ADMT has three areas of activity: Medical Device Design,
Engineering, Regulatory and Manufacturing Services; Proprietary
Electronic Medical Devices; and Eco-Friendly, Water-Based
Formulations.
The Company's headquarters, laboratories, FDA-Registered medical
device and manufacturing operations are in
Northvale,
NJ.
ADMT's multi-disciplinary team of engineers, researchers and
technologists utilize advanced technology infrastructure, such as
3-D prototyping, precision instrumentation and specialized software
and
peripherals, for
research, development and commercialization of diversified
technologies. Additional
information is available at the Company's website
admtronics.com
Except for historical information contained herein, the matters set
forth in this news release are "forward looking" statements (as
defined in the Private Securities Litigation Reform Act of 1995),
including statements regarding future revenue growth and
performance. Although ADMT believes the expectations reflected in
such forward looking statements are based upon reasonable
assumptions, there can be no assurance that its expectations will
be realized. Forward looking statements involve risks and
uncertainties that could cause actual results to differ materially
from expectations. Factors that could contribute to such
differences include those described from time to time in ADMT's SEC
filings, news releases and other communications. The Company
assumes no obligation to update information contained in this news
release.
Contact:Andre'
DiMino 201-767-6040, andre@admtronics.com